Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 17/20 | 0.57 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13697571 | 0.92 | CETP (0.48) | CETPTACR1 | |
| SCHEMBL4179335 | 0.92 | CETP (0.47) | CETPTACR1 | |
| SCHEMBL4176461 | 0.91 | CETP (0.47) | CETPTACR1 | |
| SCHEMBL4176575 | 0.91 | CETP (0.47) | CETPTBXA2RPTGDRPTGDR2 | |
| SCHEMBL4176519 | 0.91 | CETP (0.46) | CETPTACR1 | |
| SCHEMBL4179609 | 0.90 | CETP (0.46) | CETPTACR1 | |
| SCHEMBL13697573 | 0.90 | CETP (0.50) | CETPTACR1 | |
| SCHEMBL4193202 | 0.89 | CETP (0.45) | CETPTACR1PTGDR2 | |
| SCHEMBL4176315 | 0.89 | CETP (0.58) | CETPTBXA2RPTGDRPTGDR2 | |
| SCHEMBL4173895 | 0.89 | CETP (0.58) | CETPTBXA2RPTGDRPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239865-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. | 2009-09-24 | — | — | US | claimed |
| EP-1817297-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | Pfizer Products Inc. (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2006056854-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2006-06-01 | — | — | WO | claimed |
| US-20090239865-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239865-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239865-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. | 2009-09-24 | — | — | US | disclosed |
| EP-1817297-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | Pfizer Products Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006056854-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239865-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | APOB, LDLR, CETP | CETP 3/4885TACR1 2334/4885TBXA2R 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.